

## Spectrophotometric Estimation of Drugs Using Potassium Permanganate and Saffranin-O Dye Couple

Prashanthi. M and Venkateshwarlu. G\*

Department of Chemistry, University college of science, Osmania university, Hyderabad , Telangana- 500007, India.

---

**Abstract:** Simple, accurate and precise UV- Visible spectrophotometric methods have been developed for the estimation of five drugs viz., Gemifloxacin mesylate(GEM), Moxifloxacin hydrochloride (MOX), Olmesartan medoxomil (OLM), Sumatriptan succinate(SUM), Trimetazidine dihydrochloride(TMZ). The method is based on the oxidation of drugs with acidic Potassium permanganate (excess), and subsequent estimation of unreacted Potassium permanganate ( $KMnO_4$ ) by using Saffranin - O (S-O) as an analytical reagent. The proposed methods were found to be successful for the estimation of these drugs in bulk and its pharmaceutical formulations. The results of analysis have been validated statistically for linearity, accuracy, precision, LOD, LOQ, robustness and ruggedness.

**Keywords:** Gemifloxacin mesylate(GEM), Moxifloxacin hydrochloride (MOX), Olmesartan medoxomil (OLM), Sumatriptan succinate(SUM), Trimetazidine dihydrochloride(TMZ), Potassium permanganate – Saffranin – O, UV-Visible spectrophotometry and validation.

---

### I. Introduction

#### 1.1. Gemifloxacin (GEM), (Fig.1a):

It is chemically known as 7-[(4Z)-3-(Aminomethyl)-4-methoxyimino-pyrrolidin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid. It is used to treat a variety of bacterial infections [1]. This medication belongs to a class of drugs called quinolone antibiotics. Because of its physiological significance the drug has been quantitatively analyzed by different methods. A few analytical methods like HPLC [2-5], Spectrophotometry [6, 7], Spectrofluorimetry [8, 9], LC-MS [10], and Chemiluminescence method [11] developed for the estimation of GEM are mention worthy.

#### 1.2. Moxifloxacin (MOX), (Fig.1b):

It is chemically known as 1-cyclopropyl-7-[(1S, 6S)-2,8-diazabicyclo [4.3.0]non-8-yl]-6-fluoro-8-methoxy-4-oxo-quinoline-3-carboxylic acid. It is an advanced-generation, 8-methoxyquinolone derivate of fluoroquinolone antibacterial agent that is synthetic. It was discovered in 1999. Moxifloxacin is a broad-spectrum antibiotic [12] that is active against both Gram-positive and Gram-negative bacteria. It functions by inhibiting DNA gyrase, a type II topoisomerases, and topoisomerase IV, enzymes necessary to separate bacterial DNA, thereby inhibiting cell replication. Various methods cited in literature for its determinations involve, high performance liquid chromatography [13-15], liquid chromatography [16-18], voltammetry [19,20], spectrophotometry [21,22]. However, most of these methods involve time-consuming procedures, derivatization and/ or sophisticated instruments. Due to the fact that MOX is a compound of great pharmacological and analytical importance, in recent years, there has been an increased interest to develop accurate analytical methods which are valid for quantification of MOX in biological and pharmaceutical samples.

#### 1.3. Olmesartan medoxomil (OLM), (Fig.1c):

It is chemically known as 2H-1,3-dioxol-4-yl) methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1H-imidazole-5-Carboxylate. OLM blocks the vasoconstrictor effects of angiotensin 2 by selectively blocking the binding of angiotensin 2 to the AT1 receptor in vascular smooth muscle. Its action is, therefore, independent of the pathways for angiotensin 2 synthesis. Liquid chromatography [23,24], UV spectrophotometry [25] and Capillary electrophoresis [26,27] are reported in the literature. Combination methods are reported for determination of OLM with Ramipril [28] and HPTLC [29] method for Hydrochloro thiazide and OLM.

#### 1.4. Sumatriptan succinate (SUM), (Fig.1d):

It is most frequently prescribed anti-migraine drug of triptan class. It is chemically known as 3-[2-(Dimethylamino) ethyl]-N-methyl-1H indole-5-methane sulphamide succinate (1:1) base. SUM is a specific and selective 5-hydroxy tryptamine receptor [5HT<sub>1D</sub>] agonist with no effect on the other 5HT receptor [5HT<sub>2-5HT7</sub>] sub types. It is widely used for acute relief of migraine attack. SUM undergoes an extensive

biotransformation mainly through Mono amino oxidase-A. Several analytical techniques like spectrophotometric methods [30,31], Extractive spectrophotometry [32,33], HPLC [34,35] and voltammetry [36] have been reported for SUM in combination with other drugs.

### **1.5. Trimetazidine di hydrochloride(TMZ),(Fig.1e):**

It is chemically known as 1-[(2, 3, 4- trimethoxyphenyl)methyl]piperazine dihydrochloride. It is a clinically effective antianginal agent that has been used in the prophylaxis and management of angina pectoris, and in ischemia of neurosensory tissues as in Meniere's disease. Trimetazidine exhibits some cytoprotective effects on myocardial energy metabolism and exerts an anti angina effect in the absence of significant hemodynamic effects. Trimetazidine dihydrochloride has been determined in pharmaceutical formulations and biological fluids by high performance thin-layer chromatography [37], liquid chromatography [38-40].

Therefore this method was made to develop a simple spectrophotometric method for the estimation of above mentioned drugs in pharmaceutical formulation.

## **II. Methods And Materials:**

The pharmaceutical grade drugs were supplied by Arabindo pharmaceuticals and Hetero drugs Pvt. Ltd, Hyderabad. Saffranin-O, potassium permanganate (KMnO<sub>4</sub>) were purchased from S.d fine chem. Pvt. Ltd, Mumbai, India. Sulphuric acid (H<sub>2</sub>SO<sub>4</sub>) is purchased from SRL chemicals, Mumbai, India. Whatman filter paper no.42 was used for filtration purpose. All the reagents used were of analytical-reagent grade and triple distilled water was used throughout the investigation. Tablets were purchased from the local market. All absorbance measurements were recorded on Shimadzu 140 double beam spectrophotometer as well as on Thermo Nicolet 100 & Elico 159 UV-Visible single beam spectrophotometers using matched pair of Quartz cells of 10mm path length.

### **2.1. Preparation of standard stock solutions:**

KMnO<sub>4</sub> (7.6x10<sup>-2</sup>M): Stock solution was prepared by dissolving 0.1209gm of KMnO<sub>4</sub> in 100mL standard flask with double distilled water. Stock solution was further diluted to the concentration of 161.5µg mL.

Saffranin-O (1x10<sup>-3</sup>M): Stock solution was prepared by dissolving 35mg of Saffranin-O in 100mL standard flask with double distilled water. Stock solution was further diluted to the concentration of 140 µg mL<sup>-1</sup>.

Standard stock solutions of drugs were prepared by dissolving accurately weighed 40mg drug in separate 100 mL flasks. The stock solutions of GEM, MOX, OLM, SUM and TMZ were diluted with water to obtain 30µg mL<sup>-1</sup>, 24µg mL<sup>-1</sup>, 15µg mL<sup>-1</sup>, 16µg mL<sup>-1</sup> and 16µg mL<sup>-1</sup> respectively.

H<sub>2</sub>SO<sub>4</sub>: concentrated sulphuric acid (H<sub>2</sub>SO<sub>4</sub>) diluted appropriately with triple distilled water to get 0.2M acid solution.

**2.2. Construction of calibration curve:** Aliquots of pure drug solution (1.0-7.0mL) were transferred into a series of 10mL calibrated flasks. To each flask 1mL of 0.2M H<sub>2</sub>SO<sub>4</sub> acid was added followed by 1.0mL of KMnO<sub>4</sub> solution. The flasks are stoppered and contents were mixed and the flasks were heated for 10 min. These were cooled and finally, 1.0 mL of Saffranin-O solution was added to each flask and the volume was adjusted to the mark with water and mixed well. The absorbance of each solution was measured at 520 nm after 5 min.

A standard graph was prepared by plotting the absorbance versus the concentration of drugs. The concentration of the unknown were read from the calibration graph or computed from the regression equation derived using Beer's law data. Calibration curve for each drug was drawn in (Fig.2).

**2.3. Analysis of commercial dosage forms:** A quantity of finely ground tablets powder equivalent to 10 mg of drug GEM (Gemistar-320mg), MOX (Moxif-400mg), OLM (Benicar-20 mg), SUM (Sumitrex -25 mg) and TMZ (Cardimax-SR-60mg) were accurately weighed and taken in 60 mL distilled water in 100 mL volumetric flask and left for 10 min for complete dispersion and then filtered through Whatman No.42 filter paper. The residue was washed well with distilled water for complete recovery of the drug. First 10 mL portion of the filtrate was rejected and a convenient aliquot of filtrate was further diluted for the analysis within the limits of Beer's law.

Drug+known excess of KMnO<sub>4</sub> Reaction product of the drug+Unreacted KMnO<sub>4</sub>  
Unreacted KMnO<sub>4</sub> + Fixed amount of S-O Absorbance of S-O measured at 520nm.

**2.4. Method validation:** The proposed methods were validated according to guidelines of international conference on Harmonization (ICH). Under the described experimental conditions, standard experimental conditions, standard calibration curves for the studied drugs were constructed by plotting absorbance versus

concentration. Conformity with Beer's law was evident in the concentration range cited in Table-2. The linear regression equations, molar absorptivity, Sandell's sensitivity, limits of detection (LOD) and limits of quantification (LOQ) were listed in the same Table. Standard deviation, relative standard deviation, variance and standard error were calculated.

The accuracy of the method was established by analyzing the pure drug at three levels (within working limits) and the precision was ascertained by calculating the relative standard deviation (RSD) of six replicate determinations on the same solution containing the drug at three levels in Table-3. The analytical results for accuracy and precision showed that the proposed methods have good repeatability and reproducibility.

The percentage recoveries of the pure drugs using the proposed methods compared with that given by reference methods are illustrated in Table-4. The validity of the proposed method in literature is evaluated by statistical analysis between the results obtained and that of reference methods. Student's t-test and variance ratio F-test are chosen for the comparison of the results.

Values are within the permissible range reported in literature.

### III. Results And Discussion

The calibration curves for GEM, MOX, OLM, SUM and TMZ, over a concentration range of 3.0-21.0  $\mu\text{g/mL}$ , 2.4-16.8  $\mu\text{g/mL}$ , 3.0-21.0  $\mu\text{g/mL}$ , 3.2-22.4  $\mu\text{g/mL}$  and 1.6-11.2  $\mu\text{g/mL}$  respectively, were plotted and molar absorptivity for drugs were calculated at the wavelength of 520nm. The regression characteristics were reported in Table-2. The result of assay is reported in Table-3. The accuracy of the proposed method was evaluated by percentage recovery studies of the drugs.

The %RSD was less than 2%, showing high degree of precision of the proposed method. The results of the method lie within the prescribed limit, showing that method is free from interference from excipients.


### IV. Conclusion

The obtained results from the method for the determination of mentioned drugs indicates that method is simple, accurate and precise. The method is economical compared to other sophisticated analytical instruments. Hence can be used for routine analysis of commercially available formulations. The method is suitable for the determination of these drugs in tablet formulation without interference from commonly used excipients. The solvents used for the method are inexpensive and simple to prepare, and could be used in a quality control laboratory for routine drug analysis.

### Acknowledgement


The authors are thankful to the Head, Department of Chemistry, Osmania University, and Hyderabad-500007 for providing facilities.

Fig. 1: Structures of drugs



Olmesartan medoxomil (OLM),[Fig. 1c]:

Sumatriptan succinate (SUM), [Fig.1d]:



Trimetazidine di hydrochloride(TMZ)),[Fig.1e]:

Fig2: Calibration curves:




Table-1: Comparison of various techniques.

Drug	Method	Sensitivity	Recovery
GEM	1)UV-Spectrophotometry	1.5-11.25 $\mu\text{g mL}^{-1}$	99.2%
	2)LC-DAD method	0.25-20 $\mu\text{g mL}^{-1}$	99.9 %
	3)Spectrofluorimetric method	10-1000 ng $\text{mL}^{-1}$	97.6%
	4)Potentiometry	$10^{-7}$ - $10^{-2}$ $\text{ML}^{-1}$	99.4%
MOX	1) UV-Spectrophotometry	1.5-11.25 $\mu\text{g mL}^{-1}$	98.66%
	2)HPLC	20-80 $\mu\text{g mL}^{-1}$	100.7%
OLM	1)UV-spectrophotometry	5-50 $\mu\text{g mL}^{-1}$	99.75-100.43%
	2)RP-HPLC		
	3)Capillary zone electrophoresis	32-160 $\mu\text{g mL}^{-1}$	99.42%
	4)HPLC	2.0-50 $\mu\text{g mL}^{-1}$	
SUM		80-320 $\mu\text{g mL}^{-1}$	99.09%
	1)HPLC	10-100 $\mu\text{g/ml}$	99.79%
	2)HPTLC	100-1000 $\mu\text{g/ml}$	99.94-100.3%
	3)UV spectrophotometry	0.5-3.5 $\mu\text{g/ml}$	99.30%
	4)Ion association method	2-10 $\mu\text{g/ml}$	99.304%
TMZ	5)Visible spectrophotometry	4-20 $\mu\text{g/ml}$	
	1)Spectrophotometry	0.4-2.56 $\mu\text{g mL}^{-1}$	98-99.2%
	2)Spectrofluimetry	4-20 $\mu\text{g mL}^{-1}$	99.7%

Table-2: Analytical and regression parameters of spectrophotometric methods.

Parameters	GEM	MOX	OLM	SUM	TMZ
$\lambda_{\text{max}}$ nm	520	520	520	520	520
Beer's law limit( $\mu\text{g mL}^{-1}$ )	3.0-21.0	2.4-16.8	3.0-21.0	3.2-22.4	1.6-11.2
Sandell sensitivity*( $\mu\text{g/cm}^2$ )	0.0188	0.0175	0.016	0.022	0.0069
Limit of detection( $\mu\text{g mL}^{-1}$ )	1.369	1.53	1.99	0.05	0.068
Limit of quantification( $\mu\text{g mL}^{-1}$ )	4.15	4.66	6.05	0.15	0.20
Regression equation**					
Intercept(a)	-0.187	-0.003	-0.002	0.09	-0.086

Slope(b)	0.053	0.057	0.060	0.044	0.144
Correlation coefficient(r)	0.994	0.999	0.998	0.991	0.995
Standard deviation of intercept(S <sub>a</sub> )	0.022	0.0266	0.0363	0.0007	0.003
Variance(S <sub>a</sub> <sup>2</sup> )	4.84x10 <sup>-4</sup>	6.76x10 <sup>-4</sup>	10.496x10 <sup>-4</sup>	0.49x10 <sup>-6</sup>	0.09x10 <sup>-4</sup>
Standard deviation of slope(S <sub>b</sub> )	0.00141	0.0005	0.0648	0.00141	0.002

\*Limit of determination as the weight in µg per mL of solution, which corresponds to an absorbance of A = 0.001 measured in a cuvette of cross-sectional area 1 cm<sup>2</sup> and path length of 1 cm. Y\*\* = a+bX, where Y is the absorbance and X concentration of drugs in µg per mL.

**Table 3: Determination of accuracy and precision of the methods on pure drug sample.**

Drug	Taken(µg mL <sup>-1</sup> )	Found(µg mL <sup>-1</sup> )	% error	%Recovery	%RSD	Proposed method mean±S.D
GEM	1.5	1.51	0.66	100.66	0.448	100.32±0.457
	4.0	4.02	0.5	100.5		
	5.5	5.49	0.18	99.8		
MOX	1.5	1.49	0.66	99.33	0.380	99.77±0.381
	3.0	3.01	0.33	99.99		
	4.5	4.49	0.22	99.99		
OLM	2.0	2.01	0.5	100.5	1.439	99.93±1.436
	4.0	4.04	1.0	101		
	6.0	5.9	1.6	98.3		
SUM	3.0	3.01	0.33	100.3	1.778	99.93±1.778
	5.0	4.9	2.0	98		
	6.5	6.6	1.53	101.5		
TMZ	1.0	1.02	2.0	102	1.248	100.83±1.25
	4.0	3.98	0.5	99.5		
	7.0	7.01	0.14	101		

**Table-4 :Results of assay of tablets by the proposed methods and statistical evaluation and recovery experiments by standard addition method.**

Tablet	Drug taken (µg mL <sup>-1</sup> )	Drug found (µg mL <sup>-1</sup> )	Error (%)	Recovery (%)	RSD (%)	Reference Method mean±SD	Proposed Method mean±SD	t-test	F-test
Gemistar (GEM)	4.5	4.49	0.222	99.77%	0.080	99.49±0.43	99.78±0.080	1.9	0.034
	7.5	7.49	0.133	99.86%					
	10.5	10.48	0.190	99.80%					
Moxif (MOX)	3.6	3.59	0.277	99.72%	0.185	98.86±0.2	99.89±0.185	0.006	0.85
	8.4	8.39	0.119	99.88%					
	10.8	10.81	0.092	100.09%					
Benicar (OLM)	4.5	4.52	0.444	100.4%	0.299	100.1±0.19	100.05±0.300	0.785	2.49
	7.5	7.49	0.133	99.86%					
	10.5	10.49	0.095	99.90%					
Sumitrex (SUM)	4.8	4.79	0.208	99.79%	0.176	99.3±0.314	99.89±0.176	1.97	0.316
	7.0	7.01	0.142	100.1%					
	10.2	10.18	0.196	99.80%					
Cardimax-SR(TMZ)	2.4	2.41	0.416	100.41%	0.264	97.2±1.4	100.14±0.265	0.630	0.003
	5.6	5.61	0.178	100.17%					
	8.0	7.99	0.124	99.87%					

\*Average of six replicate determinations.

## References

- [1]. Ashok Kumar Bera, Amit Kumar De and Biswajit Pal. A Simple, Rapid and Validated Reverse Phase. High Performance Liquid Chromatographic Method for the Estimation of Gemifloxacin in Pharmaceutical Dosage Form. International Journal of PharmTech Research, (2014), 6(3),1011-1017.
- [2]. U. L. Narayan, B. Garnaik, S. K. Patro and S. Sahu. HPTLC Methods for Determination of Gemifloxacin Mesylate in Rabbit Plasma. British Journal of Pharmaceutical Research. (2014), 4 (14), 1707-1714.
- [3]. Narayan, U. L.; Garnaik, B. Patro, S. K.; Sahu, S. HPTLC methods for determination of gemifloxacin mesylate in rabbit plasma. British Journal of Pharmaceutical Research, 2014; 4(14):
- [4]. Abdallah, Nehad A. HPLC and densitometric TLC methods for simultaneous determination of gemifloxacin with some co-administered drugs in human plasma. Chromat Separation Techniq, (2010), 5(2), 9.
- [5]. A.R. Rote, S.P. Pingle. Reverse phase-HPLC and HPTLC methods for determination of gemifloxacin mesylate in human plasma. Journal of Chromatography B, (2009), 877(29), 3719–3723.

- [6]. Hassan, Syed Saeed U; Hayat, Uzma; Tariq, Imran; Ahmad, Irshad; Hayat, Muhammad Munawar; Uzair, Muhammad; Ansari, Muhammad Tayyab. Spectrophotometric method for the determination of Gemifloxacin mesylate in pure and tablet dosage form. Pak. J. Pharm. Sci, (2014), 27(5), 1171-1174.
- [7]. Hajera, Khan. Development and validation of a dissolution test with spectrophotometric analysis for gemifloxacin in tablet dosage form. International Journal of Research in Pharmaceutical and Biomedical Sciences, (2012), 3(1).
- [8]. Moussa, Bahia Abbas; Mahrouse, Marianne Alphonse; Hassan, Mahmoud Ali; Fawzy, Michael Gamal. Spectrofluorimetric determination of gemifloxacin mesylate and linezolid in pharmaceutical formulations: application of quinone-based fluorophores and enhanced native fluorescence. Acta Pharm, (2014), 64(1),15-28.
- [9]. Al-Tamimi, Salma Ali; Alarfaj, Nawal Ahmad; Aly, Fatma Ahmed; Al-Mohaimeed, Amal Mohammed, Spectrofluorimetric analysis of gemifloxacin mesylate in pharmaceutical formulations. Luminescence, (2014), 29(2), 127–131.
- [10]. Kadi, Adnan A.; Angawi, Rihab F.; Attwa, Mohamed W; Darwish, Hany W; Abdelhameed, Ali Saber. High throughput quantitative bioanalytical LC/MS/MS determination of gemifloxacin in human urine. Journal of Chemistry, (2010), 2013 (2013), 1155-64.
- [11]. Alarfaj, Nawal Ahmad; Aly, Fatma Ahmed; Al-Tamimi, Salma Ali; El-Tohamy, Maha Farouk. Enhanced silver nanoparticle chemiluminescence method for the determination of gemifloxacin mesylate using sequential injection analysis. J.Chem.Soc.Pak, (2013), 35(5),13-19.
- [12]. Mohammed M Hefnaw, Atef M Homoda, Mohammed A Abounassif, Amer M Alanazi, Abdulrahman Al-Majed and Gamal A Mostafa. Potentiometric determination of moxifloxacin in some pharmaceutical formulation using PVC membrane sensors. Chemistry Central Journal (2014), 8(59), 1-8.
- [13]. T Lemoineb, D Breilha, b, D Ducintb, J Dubrezc, J Jougonc, J.F Vellyc, M.C Sauxa,b. Determination of moxifloxacin (BAY 12-8039) in plasma and lung tissue by high-performance liquid chromatography with ultraviolet detection using a fully automated extraction method with a new polymeric cartridge. Journal of Chromatography B: Biomedical Sciences and Applications.(2000), 742(2), 247-254.
- [14]. Aleksandra Laban-Djurđevića, Milena Jelikić-Stankovb, Predrag Djurđevićc, Optimization and validation of the direct HPLC method for the determination of moxifloxacin in plasma. Journal of Chromatography B. (2006), 844(1), 104-111.
- [15]. Boubakar B. Baa, Renaud Etiennea, Dominique Ducinta, Claudine Quentinb, Marie-Claude Sauxa. Determination of moxifloxacin in growth media by high-performance liquid chromatography. Journal of Chromatography B: Biomedical Sciences and Applications.(2001), 754(1), 107-112.
- [16]. Karthick Vishwanathan, Michael G Bartlett, James T Stewart. Determination of moxifloxacin in human plasma by liquid chromatography electrospray ionization tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis.(2002), 30(4), 961–968.
- [17]. A.K. Hemanth Kumar, Geetha Ramachandran. Simple and rapid liquid chromatography method for determination of moxifloxacin in plasma. Journal of Chromatography B. (2009), 877(11-12), 1205–1208.
- [18]. D.H. Vu, R.A. Koster, J.W.C. Alffenaar, J.R.B.J. Brouwers, D.R.A. Uges. Determination of moxifloxacin in dried blood spots using LC–MS/MS and the impact of the hematocrit and blood volume. Journal of Chromatography B. (2011), 879(15-16), 1063–1070.
- [19]. Magno Aparecido G. Trindade, Gláucia Maria da Silva, Valdir Souza Ferreira. Determination of moxifloxacin in tablets and human urine by square-wave adsorptive voltammetry. Microchemical Journal. (2005), 81(2), 209–216.
- [20]. N. Erk. Voltammetric behaviour and determination of moxifloxacin in pharmaceutical products and human plasma. Analytical and Bioanalytical Chemistry. (2004), 378(5), 1351-1356.
- [21]. Maha A. Sultan, New, simple and validated kinetics spectrophotometric method for determination of moxifloxacin in its pharmaceutical formulations. Arabian Journal of Chemistry. (2009), 2(2), 79–85.
- [22]. A Speciale, R Musumeci, G Blandino, I Milazzo, F Caccamo, G Nicoletti. Minimal inhibitory concentrations and time-kill determination of moxifloxacin against aerobic and anaerobic isolates. International Journal of Antimicrobial Agents. (2002), 19(2), 111–11
- [23]. Chaitanya Prasad MK, Vidyasagar G, Sambashivarao KRS and Ramanjaneyulu S., Development of RP-HPLC method for estimation of olmesartan medoxomil in tablet dosage forms, Der pharma chemica, 2011, 3 (6), 208-212.
- [24]. Gaurang P. Pandya and Hitendra S. Joshi, Development and validation of stability indicating HPLC assay method for simultaneous determination of Amlodipine besylate, olmesartan medoxomil and hydrochlorothiazide in tablet formulation, Der pharmacia sinica, 2013, 4(2): 145-152.
- [25]. Hemke A.T., Bhure M.V, Chouhan K.S, Gupta K.R. and Wadodkar S.G., UV Spectrophotometric determination of hydrochlorothiazide and olmesartan medoxomil in pharmaceutical formulation, EJournal of chemistry, 2010, 7 (4), 1156-1161.
- [26]. Mustafa CELEBER, Incilay SUSLU & Scide ALTINOZ, Saimultaneous determination of Olmesartan medoxomil and Amlodipine besylate in pharmaceutical formulations by Capillary zone Electrophoresis, Latin American journal of Pharmacy, 2011, 30 (4), 753-758.
- [27]. Mustafa CELEBER, Scide ALTINOZ, Development of a capillaryzone electrophoresis method for the indirect determination of olmesartan medoxomil and determination of Hydrothiazide in synthetic tablets, 2007, 27, 119-130.
- [28]. Santosh R Karaigi, Simpi C.C., Kalyanee N.V, Simultaneous first derivative UV spectrophotometric estimation of ramipril and Olmesartan, RGUHS J Pharm Sci, 2012, 2 (1), 78-82.
- [29]. Hemke A.T., Bhure M.V, Chouhan K.S, Gupta K.R. and Wadodkar S.G., Development of RRP-HPLC method for estimation of Hydrochlorothiazide and olmesartan medoxomil in pharmaceutical formulation, Research journal of pharmaceutical, biological and chemical sciences, 2010, 1 (2), 78-84. [30]. Prashanth KN, Basavaiah K, Raghu MS. Permanganometric determination of Sumatriptan succinate in pure drug and pharmaceutical formulation. The Journal of Pharmaceutical Sciences, 37 (2), 2013, 95-106.
- [31]. Prashanth KN, Basavaiah K, Raghu MS. Utilization of N-bromosuccinamide as a brominating agent for the determination of Sumatriptan succinate in bulk drug and tablets. International journal of Analytical chemistry, 934357, 2013, 12
- [32]. KalyamaRamu B, Raghu babu K. Ion association method for the determination of Sumatriptan succinate from tablet dosage forms using Tropaeolin. International journal of Pharmacy and Pharmaceutical sciences, 3(3), 2011, 175-178.
- [33]. KalyamaRamu B, Raghu babu K. A simple visible spectrophotometric determination of Sumatriptan succinate from pharmaceutical formulations. Pharma chemical, 3(1), 2011, 223-228.
- [34]. Reddy YerramRamkoti, Kumar Kakumani Kishore, Reddy MRP, Mukkanti K. Rapid simultaneous determination of Sumatriptan succinate and naproxen sodium in combined tablets by validated ultra performance liquid chromatographic method. Journal of Analytical and bioanalytical techniques, 2(3), 2011.
- [35]. Bebawy LI, Moustafa AA, Abo Talif NF. Stability indicating methods for the determination of Sumatriptan succinate. Journal of pharmaceutical and biomedical analysis, 32(6), 2003, 1123-1133.

- [36]. Sorm Agar, Kamal Fernandez Alvarez, Jose Maria, Hua chi, Smyth Malcolm R, Munden Ray. Differential pulse voltammetric determination of Sumatriptan succinate (1:1) in tablet dosage forms. *Journal of pharmaceutical and biomedical analysis*, 10(1), 1992, 17-21.
- [37]. Thhoppil SO, Cardoza RM, Amin PD. (2005). *J. Pharm, Biomed. Anal.*, 25, 15-20.
- [38]. Thhoppil SO, Cardoza RM, Amin PD. (2001). *J. Pharm, Biomed. Anal.*, 25, 191-195.
- [39]. Bari VR, Dhorda UJ, Sundaresan M. (1999). *Indian Drugs*, 36, 289.
- [40]. Courte S, Bromet N, Chromatogr H. (1981), 224, 162-167.